Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction

Patrizia Sola, Elisa Merelli, Roberto Marasca, Maria Poggi, Mario Luppi, Marcello Montorsi, Giuseppe Torelli

Abstract
A possible involvement of human herpesvirus 6 (HHV-6) infection in the pathogenesis of multiple sclerosis (MS) was investigated. The immunofluorescence analysis of sera from 126 MS patients showed significantly higher anti-HHV-6 antibody titres in MS sera than in 500 normal controls. A polymerase chain reaction (PCR) assay of the peripheral blood mononuclear cell (PBMC) DNAs of 31 MS patients and 24 normal subjects was positive in one normal control and in one MS patient. The Southern blot analysis indicated an unexpectedly high level of viral sequences in the MS patient, but not in the control. Since viral sequences are rarely present in MS subjects, the high anti-HHV-6 antibody titres found in MS are likely to be related to immune impairment rather than reactivation of a latent infection.

(J Neurol Neurosurg Psychiatry 1993;56:917–919)

Human herpesvirus 6 (HHV-6) was first isolated in 1986 from six patients with lymphoproliferative disorders, two of whom also had HIV antibodies. This virus is selectively cytopathic to freshly cultured CD4+ T lymphocytes, although it may be infectious at lower levels for other cell lines, including B cells, macrophage/microcytotes, and glial cells. HHV-6 is the causative agent of the exanthem subitum of children, while the adult primary infection has been related to chronic fatigue syndrome. The infection is widespread, its seroprevalence in healthy adult populations ranging between 50% and 85%. Seroconversion occurs early in childhood, and the antibody titres decrease in a normal population after age 40. HHV-6 sequences have been detected by polymerase chain reaction (PCR) in saliva samples and in mononuclear cells of the peripheral blood of healthy adults, suggesting that the viral genome may persist in the oropharynx and that normally only rare cells in the peripheral blood of healthy individuals are infected. HHV-6 is frequently found, and sometimes isolated, in HIV infected patients. Since this herpesvirus induces CD4 receptor, is able to transactivate the HIV long terminal repeat, and to productively coinfect human T cells with HIV, a possible role in the pathogenesis of AIDS has been suggested.

High titres of anti-HHV-6 antibodies and the presence of HHV-6 genomic sequences are frequently associated with immune disorders. Up to now, a large number of viral agents have been investigated in multiple sclerosis (MS), but not HHV-6. We were interested in studying the HHV-6 infection in MS patients because of its biological characteristics, including its strong CD4+ T cell tropism, synergetic action with other viruses, and the occurrence of the infection early in human life with persistence in latent form in the adults.

Materials and methods
We tested for anti-HHV-6 antibody by indirect immunofluorescence analysis (IFA) the serum and CSF samples collected from 126 MS patients (47 men and 79 women, mean age 35 years, range 13–70). The sera from 500 healthy, HIV-negative, blood donors (250 men and 250 women, mean age 44 years) were also examined to establish a control value for a normal population. Indirect IFA was performed on HHV-6 infected HSB-2 cells as described by Ablashi et al. Serum samples were examined at 1:40, 1:80 and 1:160 dilutions. CSF samples were examined undiluted and diluted 1:40 and 1:80. Antibody titration was performed double blind by two operators.

PCR analysis was performed according to Torelli et al. in the DNAs extracted from the peripheral blood mononuclear cells (PBMCs) of 31 MS patients and of 24 blood donors. The oligonucleotides used as primers and probes were synthesised on an automated solid phase synthesiser (Applied Biosystems Inc, Mod 381A), by standard phosphoramidite chemistry. Two sets of primers and probes were used. One set, representing a portion of the gene for the major capsid protein, has the following sequence: (1) 5'ATTAGGACCGGATGGCTC3' as sense primer, (2) 5'GTTGTAGTGTGTCGAATGGCA3' as antisense primer, (3)
5'TCCCGGCGTACGCTGTAATTGAGTAS3' as internal probe. The second set, representing a portion of the ZVH14 segment, has the following sequence: (1) 5'CCCATTTAGATTTTCCGACACCCCTCTCCG3' as antisense primer, (2) 5'TTCGGGACGTTATGCTGAGCAGTTCG3' as antisense primer, (3) 5'CCTTAAAAATTTACACCTCCATTTCCATTTT3' as internal probe. Thirty cycles of amplification were performed with an automatic thermal cycler (MJ Research, Cambridge, MA, USA). The amplification products, a 300 nucleotide segment for the first set and a 186 nucleotide segment for the second set, were then subjected to electrophoresis, transferred to a nylon membrane by vacuum blotting, and hybridised with an oligonucleotide probe end-labelled with γ32P-ATP. The autoradiography was then performed for 2 and 7 days at −80°C. A positive control was represented by HHV-6 infected HSB-2 DNA. Two negative controls (a human placental DNA and a reaction mixture without DNA) were used for each group of 10 samples examined. In Southern blot analysis the pZVH14 plasmid described by Josephs et al was used as probe.

Results
We found significantly higher anti-HHV-6 IgG antibody titres in MS patients in comparison with the blood donors group at IFA analysis (table). Data obtained with sera at 1:20 dilution were disregarded because of the non-specific immunofluorescence detected in control uninfected cells.

Only one out of 31 MS DNA samples showed a strong signal with both sets of primers in the PCR analysis. The same sample was positive when analysed by Southern blot technique using as probe the pZVH14 plasmid, containing 9 kb of the HHV-6 genome including the segment amplified by one set of primers. To avoid false positive results due to possible contaminations, both PCR and Southern analysis were performed on three different DNA samples extracted from cell pellets collected at different intervals during a remission phase of the disease. The DNA of the positive patient was digested with Eco RI, Hind III and Bam HI restriction enzymes and hybridised with the pZVH14 plasmid. Then it was compared with the DNAs extracted from normal human pla-
centa and from HSB-2 cells infected by HHV-6, strain GS. The pZVH14 sequence of this case compared with the same sequence of GS strain, showed the same restriction fragment length polymorphism (RFLP), with all the enzymes used. The PCR assay performed on the DNAs of 24 normal subjects showed only one positive case. In this case the signal was very faint and the Southern analysis was negative, suggesting that the number of copies of HHV-6 sequences detected is much lower than in the positive MS patient.

Both the two PCR positive cases were negative for serum anti-HHV-6 antibody at IFA analysis.

Discussion
Our results on anti-HHV-6 antibody titres in the blood donors group are in good agreement with published data, and suggest that HHV-6 infection is widespread in our region, as well as in a number of other countries. Moreover, the use of 1:40 dilution makes unlikely a non-specific reaction, while a possible immunological crossreactivity between HHV-6 and other herpesviruses has been ruled out by several authors.

To explain the high anti-HHV-6 antibody titres in MS, it may be speculated that in this disease the impairment of the cellular immune response may lead to the reactivation of an HHV-6 latent infection. This reactivation may in turn determine an increase of anti-HHV-6 antibody titres. This explanation cannot be ruled out; however, it seems unlikely in view of our PCR data, since we found HHV-6 sequences in the PBMC DNA of only one out of 31 MS patients, in spite of the known lymphotropism of this virus. In the absence of a satisfactory explanation we can only say that the immune system in MS is activated against HHV-6, in the absence of detectable viral genome.

In nine MS patients anti-HHV-6 IgG were present also in the CSF. Because only two out of nine MS patients with CSF anti-HHV-6 antibodies show BBB damage, we suggest that in these patients the immune stimulation leads to the synthesis of these antibodies by intrathecal lymphocyte clones, as confirmed by the high CSF IgG index frequently found. Within the limits of sensitivity of our PCR assay, two positive cases were found: one MS patient and one healthy control, both negative for HHV-6 antibody. We have no explanation for this discrepancy which is typically associated with latent infection or could be due to immune disregulation. In spite of the use of two different sets of primers, the molecular tests performed do not allow us to establish with absolute certainty the presence in PBMCs of complete HHV-6 genomes. However, the amplified sequences are HHV-6 specific, because the primers used did not cross hybridise with normal human DNA or with other herpesvirus DNAs.

The positive MS patient showed an unexpectedly high number of copies of HHV-6 sequences, so that these sequences were easily detected.

<table>
<thead>
<tr>
<th>Sample dilution</th>
<th>MS (n = 126)</th>
<th>BD (n = 500)</th>
<th>χ²</th>
</tr>
</thead>
<tbody>
<tr>
<td>serum 1:40</td>
<td>74%</td>
<td>41%</td>
<td>42.1*</td>
</tr>
<tr>
<td>serum 1:80</td>
<td>74%</td>
<td>18%</td>
<td>51.6*</td>
</tr>
<tr>
<td>serum 1:160</td>
<td>50%</td>
<td>4%</td>
<td>44.7*</td>
</tr>
<tr>
<td>CSF undiluted</td>
<td>7%</td>
<td>nd</td>
<td></td>
</tr>
<tr>
<td>CSF 1:40</td>
<td>2%</td>
<td>nd</td>
<td></td>
</tr>
<tr>
<td>CSF 1:80</td>
<td>1%</td>
<td>nd</td>
<td></td>
</tr>
</tbody>
</table>

nd = not determined. *p < 0.0005.
detectable by a standard Southern analysis, contrary to the normal positive control. Only an in situ hybridisation assay would allow us to establish if there are few cells with a high number of HHV-6 sequences or several cells carrying few HHV-6 molecules. The faint positivity in the PCR assay of the normal positive subject suggests that in this case only a rare cell in the peripheral blood is infected with few copies of HHV-6. The difference between the two positive cases could be related to the immune impairment of MS, which would make possible the expansion of a latent infection not allowed by an intact immune system. Otherwise, the immune impairment of the disease could be viewed as a consequence rather than as the origin of the high viral titres.

Since HHV-6 is able to infect other cells beside T lymphocytes, a reason for these results may be that the virus remains latent in cells other than PBMCs, perhaps in the oligodendrocytes. Lastly, it is also impossible to exclude that variant HHV-6, not well hybridising to our primers, may be present in the PBMCs examined.

At present, we cannot draw any conclusion in favour of or against a possible role of HHV-6 in the pathogenesis of some MS cases. Moreover, the possibility that HHV-6 proteins may cause the transactivation of other cellular or viral genes contributing in this way to the immune derangement of MS cannot be ruled out.23 We emphasise that further refining of antibody test systems, experience with larger numbers of subjects, and careful prospective and molecular studies are necessary before conclusions can be made regarding the relations between the MS and HHV-6 infection.

This work was supported by a grant and a fellowship (PS) from the Associazione Italiana Sclerosi Multipla (AISM) and by ICSC-World Laboratory, Geneva, as part of project MCD2.


Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction.

P Sola, E Merelli, R Marasca, M Poggi, M Luppi, M Montorsi and G Torelli

J Neurol Neurosurg Psychiatry 1993 56: 917-919
doi: 10.1136/jnnp.56.8.917

Updated information and services can be found at:
http://jnnp.bmj.com/content/56/8/917

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/